A PHASE 4 TRIAL ASSESSING THE IMPACT OF RESIDUAL INFLAMMATION DETECTED VIA IMAGING TECHNIQUES, DRUG LEVELS AND PATIENT CHARACTERISTICS ON THE OUTCOME OF DOSE TAPERING OF ADALIMUMAB IN CLINICAL REMISSION RHEUMATOID ARTHRITIS (RA) SUBJECTS (PREDICTRA):